Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Rising Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of TAK-788 Followed by Crossover Evaluation of the Effects of a Low-Fat Meal on TAK-788 Pharmacokinetics in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2018
At a glance
- Drugs AP 32788 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 20 Jul 2018 Planned number of patients changed from 56 to 72.
- 20 Jul 2018 Planned End Date changed from 7 Jul 2018 to 22 Aug 2018.
- 20 Jul 2018 Planned primary completion date changed from 7 Jul 2018 to 22 Aug 2018.